… pivotal Phase III MOTION trial of vimseltinib, against placebo … previously, except for treatments with imatinib or nilotinib. The study … Phase I/II trial findings. According to … member of Ono Pharmaceutical, develops medicines utilising its switch-control …

… remedies in the realm of drug development.6 Despite their considerable medicinal … co-loaded with imatinib into the hydrophobic … for the treatment of bronchopulmonary aspergillosis. … polysaccharide nanocrystals as pharmaceutical excipients. Carbohydr Polym. …

… tyrosine kinase inhibitors (TKIs) like imatinib, nilotinib, dasatinib, and bosutinib. However … of the phase 3 ASC4FIRST trial. These data demonstrated superior molecular … molecular response and considering future treatment-free remission, are central to …

… to comedicate with statins.85 Antidepressants Fluvoxamine is commonly … adverse events. Gemfibrozil-Imatinib Both CYP2C8 and … and clinical pharmaceutical care. Develop new drugs that are … CYP2C8 perpetrators (dose, treatment course, systemic concentrations, …

… that could reshape drug discovery, researchers at Harvard Medical School (HMS) have … treatments such as kinase inhibitors—the authors cite imatinib as an example—drugs … and drug-based experiments, asking the tool to predict various treatment options …

… of imatinib (Imkeldi), which was FDA approved in 2024 for the treatment of … in collaboration with medical oncologists for toxicity management, drug interactions, and supportive … to] cut a medication and giving them pill splitters to make sure …

… ) negativity outcomes following treatment with ponatinib (Iclusig) or imatinib (Gleevec) in patients … PhALLCON trial (NCT03589326) evaluated the efficacy and safety of ponatinib vs imatinib … vs the imatinib arm, he stated. By the end of treatment, the …

… , therapeutic, and biotechnological potential.53 Their … medicine clinical translational pathway, including preclinical studies, clinical trials … trial of imatinib plus binimetinib in patients with treatment … -kinase targeting drugs for patient stratification …

… have kept essential medicines affordable, particularly for … generic cancer drugs. For instance, Beacon Pharmaceuticals produces Tagrix, … patent on the leukaemia drug imatinib, ensuring generics continued. … programmes for cancer treatment are needed to shield …

… transforming diagnosis, prognosis and treatment strategies for systemic mastocytosis (SM … monitor disease progression and treatment response. Treatment therapies are also increasingly … target KIT p.D816V, while imatinib may benefit patients with alternative …